trending Market Intelligence /marketintelligence/en/news-insights/trending/In4JyfZTc7vrgYl4uwXbCw2 content esgSubNav
In This List

Biogen completes spinoff of hemophilia unit

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


Biogen completes spinoff of hemophilia unit

Biogen Inc. completed the spinoff of its global hemophilia unit.

The new company, Bioverativ, is an independent publicly traded global biotechnology company specializing in hemophilia and other rare blood disorders, Biogen said in a news release.

Bioverativ common stock will begin regular way trading Feb. 2 on the Nasdaq Global Select Market under the symbol BIVV.

Biogen was advised by Goldman Sachs & Co. and Guggenheim Securities LLC.